FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 575 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New on NCI’s Websites for December 2021 December 29, 2021 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 New obesity strategy is a ‘landmark day for the nation’s health’... July 27, 2020 Load more HOT NEWS Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... EMA Recommends Extension of Therapeutic Indications for Selpercatinib
